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Abstract  
 
African Traditional Medicines (ATMs) serve as a major source of primary healthcare for African people.  The reasons 
for their use range from easy access, affordability, beliefs in traditional systems and long term safety.  ATMs have been used to 
treat individuals infected with HIV and therefore need scientific validation; a view supported by Traditional Health Practitioners 
(THPs). This study aimed to evaluate the in vitro cytotoxicity, immune modulatory and anti-HIV activities of traditional multiple 
herbal preparations from local THPs. Ugambu, Ihashi, Product Nene, Product Blue, SPNa and SDKc ATM were supplied by local 
THPs.  Changes in adenosine triphosphate (ATP) & glutathione (GSH) over 24 hours were measured using luminometry. Changes 
in 12 cytokines were assayed using an ELISA-based absorbance assay.   Protective effects against HIV killing of MT-4 cells were 
tested using the XTT assay and antiviral activity was measured using an HIV-1 viral load assay. Cyclosporine and AZT were used 
as positive controls. Ugambu, Ihashi, Product Nene and SDKc induced a dose dependent toxicity on treated PBMCs by reducing 
ATP and GSH at high doses (p< 0.001). These medicinal preparations, along with SPNa, showed immunomodulatory activity by 
significantly (p< 0.001) changing the secretion of pro-inflammatory cytokines. Product Blue stimulated the levels of ATP and 
GSH in treated PBMCs at all doses however this product did not show any immunomodulatory activity on cytokine secretion 
when compared to control cells.  Ugambu, Ihashi, Product Nene showed promising anti-HIV activity relative to AZT (p< 0.01). 
This study has shown that some of these traditional medicinal preparations have at least one or all the properties of 
immunostimulation, immunomodulation or antiretroviral effects. The mechanism of action of the shown activities should further 
be investigated.  
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Introduction 
 
Traditional health practitioners (THPs) serve as primary healthcare providers for a large population of African people. 
Traditional medicines from these THPs are preferred by African people because of their perceived safety, long history of their use 
and because they are easily accessible, among other reasons. The use of these traditional or herbal medicines in the African 
continent is largely based on oral tradition within the family or community (WHO, 2005; Tshibangu et al., 2004). Worldwide, the 
trend has also shifted towards the use of traditional medicines due to concerns about the costs, invasiveness and potential for 
toxicity of conventionally mainstream remedies (Cowan, 1999). 
With the spread of HIV and AIDS, there has been an increase in traditional medicine preparations which purport to have 
immune “boosting” or modulatory activity. The approach of African traditional medicines (ATM) to fighting infections has the 
concept of “boosting the immune system” as one of its central pillars. Therefore it is important to study the effects of ATM on the 
immune response. Regarding herbal medicines, immunomodulators may be defined as herbal medicinal extracts that modify the 
immune response via regulation of cytokines, hormones, neurotransmitters, and other peptides. Many herbal medicinal extracts 
have immune modulatory activity on at least one cytokine (Spelman et al., 2006). 
The immune system is increasingly playing a role in progression of chronic diseases for which conventional drugs have 
limited ability to treat and especially prevent. Therefore it appears sensible to target the immune response in order to alter the 
threat of certain chronic diseases (Haddad et al., 2005). Strengthening of the immune response is very important in debilitating 
conditions such as cancer and AIDS.  The immune system is responsible for the complex task of providing defense against a vast 
array of potential pathogens, whilst ensuring that the same protective mechanisms are not turned against self (Lowe and Lin, 
2000). The rise in antibiotic resistance and the decline in the development of new classes of conventional antibiotics have 
necessitated development of new strategies in the treatment of microbial infections. Because the primary target of an 
immunomodulatory treatment is the host and the effects on the pathogen are exerted indirectly via augmentation of the immune 
response, the selective pressure for pathogen resistance to the drug is minimized (Nijnik et al., 2010). 
Most of the studied herbal medicinal extracts are made of a single plant while most of the traditional medicines are 
made up of two or more plants mixed together. Although multiple herbal mixtures are extensively studied in the Far East these 
approaches are only beginning to become available to Western scientists. Most African traditional medicines follow the same 
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concept of multiple herbal mixtures. With an increase in the popularity and attractiveness in Western society of complementary 
and alternative medicine (CAM), there is increasing interest within the scientific community in studying the safety, efficacy and 
mechanism of multiple herbal medicines (Chen et al., 2002). Studies on traditional multiple herbal preparations are also becoming 
of interest to South African scientists (Bessong et al., 2004; Tshibangu et al., 2004; Ndhlala et al., 2009; Ndhlala et al., 2010). We 
therefore aimed to study the in vitro cytotoxicity, immune modulatory and anti-HIV activities of traditional multiple herbal 
preparations from local THPs.     
 
 
Materials and Methods 
Reagents and equipment  
 
RPMI-1640 with HEPES buffer (25mM), foetal calf serum (FCS), penstrep-fungizone (PSF), and L-glutamine were 
purchased from Adcock Ingram (SA). Normal whole blood was obtained from the South African National Blood Supply 
(SANBS). Histopaque 1077, 2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide (XTT) kit and 
cyclosporine were purchased from Sigma Aldrich (USA). Ethanol was bought from Merck Chemicals (SA). Promega CellTiter-
Glo™ Luminescent Cell Viability was purchased from PromegaTM (USA). The Multi-Analyte Profiler ELISArrayTM Kit was 
purchased from SABiosciences (USA). Modulus™ Microplate Luminometer was from Turner BioSystems (USA). The 96-well 
plate reader was acquired from Bio-Tek (SA), NucliSens HIV-1 EasyQ assay kit was purchased from BioMerieux, Marcy I’Etoile 
(France). 
 
Preparation of medicinal plant extracts 
 
The herbal preparations were obtained from local THPs who consented to their products being part of this research. The 
participation of THPs was protected under a material transfer agreement (MTA) signed between each THP and the University of 
KwaZulu Natal (UKZN). Some of the medicinal preparations are commercially available while others are prescribed by THPs 
during consultations with their patients. For the purpose of this paper the results of the following products will be presented: 
Ugambu, Ihashi, Product Nene, Product Blue (Spray), SPNa and SDKc. The medicinal preparations were requested to be freshly 
prepared from THPs for in vitro assays. Those supplied in liquid form were autoclaved and filter-sterilised under vacuum twice 
through 0.22 µm filters for tissue culture assays. The samples were preserved by freeze drying and stored at -20 °C for later use. 
Medicinal preparations supplied by THPs in unextracted plant material form were extracted according the healers instructions 
(boiled in distilled water), cooled over night and then autoclaved, filter-sterilised under vacuum and preserved as described above. 
The prepared extracts were then diluted into different treatment doses using cell culture media (CCM). The dilutions were 
prepared on the day the cells were treated. 
 
Isolation of peripheral blood mononuclear cells (PBMCs) from whole blood 
 
Normal whole blood from healthy volunteers acquired (from the SANBS research in EDTA coated containers) after 
prior informed consent was obtained in line with the South African Ethical Advisory Board was carefully layered onto equal 
amounts of Histopaque 1077 then centrifuged at 400 g for 30 minutes at 25 °C. After centrifugation, the buffy coat layer, 
containing PBMCs, was isolated and washed twice in phosphate buffered-saline (PBS, 5 ml), (1150g for 20 minutes at 25 °C).The 
isolated PBMCs were diluted in RPMI-1640 and pooled into one tube. A cell count of 1.5- 2 × 106 cells/ml was determined using 
the trypan blue method to standardise the cell dilution.  
  
Treatment of PBMCs with medicinal preparations     
 
Aliquots of the cell suspension (2 ml) were transferred into each well in a 6-multiwell plate. Dilutions of the medicinal 
extracts (2 ml) in cell culture media were then added to each of the treatment wells. Different doses of cyclosporine were used as 
positive controls and untreated control samples were also included as reference samples. The 6-well plates were then incubated 
for 24 hours at 37 °C in a 5% CO2 incubator. 
 
Cell viability assay 
 
Following the incubation of treated cells for 24/48 hours, a 100 µl of cells from each treatment concentration was 
pipetted into three different wells of a white opaque 96-well plate. The CellTiter-Glo Reagent (Promega, cat number: G7570) was 
mixed immediately before use and was added to the wells with treated cells at 100 µl per well. The plate was shaken on a plate 
shaker for 2 minutes at 30 g. This plate was then incubated in the dark for 10 minutes at room temperature and the relative light 
units (RLU) of the samples were measured in a luminometer following the manufacturer’s instructions. A dose response curve 
was also generated for the ATP levels using the RLU and the dilutions of medicinal preparations and different control samples. 
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Intracellular glutathione assay 
 
Changes in intracellular content of treated and control samples were measured using a luminometry based GSH-Glo 
assay kit from Promega (cat number: V6911). Following the incubation of treated cells for 24 hours, the cell culture media was 
removed from experimental samples. These samples were washed twice with PBS and a 100 µl of cells from each treatment 
concentration was pipetted into three different wells of a white opaque 96-well plate. The GSH-Glo reagent for suspension 
cultures was prepared by diluting the Luciferin-NT substrate and Glutathione-S-Transferase 1:50 in GSH-Glo reaction buffer. 
Each reaction (well) of a 96-well plate required 50 µl of the GSH-Glo reagent and the plate was then incubated in the dark for 30 
minutes at room temperature. The luciferin detection reagent was prepared by transferring the contents of one bottle of luciferin 
detection buffer to the bottle of lyophilised luciferin detection reagent. The contents were mixed by inversion several times until 
the substrate was thoroughly dissolved. Each reaction (well) of a 96-well plate required 100 µl of the luciferin detection reagent 
meaning the luciferin detection reagent needed to be 2:1 with the GSH-Glo reagent and this incubated for 15 minutes in the dark 
at room temperature. At the end of the two step reaction the plate was read using a luminometer by following manufacturer’s 
instructions.  
 
Cytokine expression assay 
 
The Multi-Analyte Profiler ELISArray assay kit (SA Biosciences, cat number: MEH-004A) is designed to be used with 
supernatants from treated cells or with serum from whole blood. It is a variation of the normal ELISA kit which uses absorbance 
instead of fluorescence to read the final results. The kit also does not give the exact concentration of each cytokine in pico or 
nanograms as a normal ELISA kit but differences in absorbance readings between controls and treated samples gives changes in 
cytokine secretion.  For the purpose of this research, cytokines were analysed from supernatants of treated PBMCs.  Each kit 
included 96-well plate coated with antibodies for the various cytokines in the microarray. Each row of the plate from 1 to 12 
represented a single cytokines in the following order:  IL 1α, IL 1β, IL 2, IL 4, IL 6, IL 8, IL 10, IL 12, IL 17α, IFN-γ, TNF-α, and 
GM-CSF. The kit had negative and positive method controls. Each sample was assayed in duplicate.  Briefly, incubation of the 
samples in the 96-well plates allowed the capture antibodies to bind their specific protein of interest. After washing away unbound 
protein with wash buffer, biotinylated detection antibodies (50 µl) were added to the wells to also bind the captured analyte. 
Following another wash, an avidin-horseradish peroxidase conjugate (100 µl) was added. The wells were again washed and the 
colorimetric substrate solution was added, developing to a blue colour in direct proportion to the amount of protein analyte 
present in the initial sample. The colour development was stopped by adding the stop solution, and the absorbance was read at 450 
nm with reference at 570 nm in a microplate reader as per manufacturer’s instructions.  
 
2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide (XTT) Screening Assay 
 
The cytotoxic and potential antiviral effects of the plant extracts were determined using the In Vitro Toxicology assay 
kit XTT based (Sigma-Aldrich, Missouri, USA) (Scudiero et al., 1988; Weislow et al., 1989; Roehm et al., 1991). Briefly, MT-4 
cells were seeded into the wells of 96-well culture plates at 6 x105 cells/ml. The virus stain HTLVIIIB was used to infect MT-4 
cells at 100-300 TCID50. Five-fold dilutions of the plant extracts were added to the plate. The plate was incubated for 5 days at 
370C in a CO2 incubator. After 5 days, the XTT salt was added to the wells and incubated for 4 hours at 370C in a CO2 incubator 
to determine the viability of the cells. The absorbances were read at 450nm (reference 620nm). The Inhibitory Concentration at 
50% (IC50), Effective Concentration at 50% (EC50) and Selectivity Index (SI) were calculated for each substance.  
 
HIV-1 Viral load assay 
 
MT-4 cells were seeded into 6 well plates at 1x106 cells/ml. Ten-fold dilutions were performed on the plant extracts and 
added to the plates. The cells and extracts were incubated for 30 minutes to achieve drug/cell equilibrium. HTLVIIIB was added at 
100 TCID50 to the plates and incubated for 3 hours. Cells were washed twice with PBS and centrifuged at 350 x g for 5 minutes. 
The cells were resuspended in RPMI-1640 containing the plant extracts at varying concentrations. The plates were incubated at 
370C in CO2 for 5 days. Supernatant for viral load testing was removed from each well at days 0, 1, 3 and 5. The NucliSens HIV-1 
EasyQ assay (BioMerieux, Marcy I’Etoile, France) was used to quantify the virus. The results were represented graphically and 
compared to the known antiviral activity of AZT. 
 
Statistical analyses 
 
Data analysis was done on Microsoft Excel, MicrosoftTM Corporation, USA, to obtain descriptive statistics.  The 
different levels of significances within the separate treated groups were analysed using one-way analysis of variance (ANOVA) 
and the differences between the treated cells and the control cells were analysed in GraphPad Instat software (version 3) using the 
Tukey-Kramer multiple comparison test. Differences with p< 0.05 were considered statistically significant. 
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RESULTS 
Cell viability assay 
 
Cell viability results are illustrated in Figure 1 (A-G). Cyclosporine, a positive control, induced a decrease in cell 
viability with increase in treatment dose (Figure 1A). High doses of Ugambu (Figure 1B) significantly (p< 0.001) decreased cell 
viability while high dilutions were not cytotoxic to treated leukocytes when compared to untreated cells. All doses of Product 
Blue did not show any cytotoxicity but seemed to stimulate viability of immune cells (p< 0.001) (Figure 1C).  
Ihashi was shown to be highly cytotoxic to immune cells at high doses up to a dilution of 1/200 (p< 0.001). Low doses 
of this product were tolerated by treated PBMCs when compared to the untreated control (Figure 1D). Product Nene and SDKc 
also demonstrated dose dependent effects on treated immune cells (Figures 1E and G). Both products were significantly (p< 
0.001) cytotoxic to PBMCs at high doses when compared to untreated cells but Product Nene demonstrated higher cytotoxic than 
SDKc. SPNa doses significantly reduced cell viability even at medium doses (1/300) (Figure 1F).        
 
Intracellular glutathione assay 
 
Changes in intracellular GSH levels reflect the number of viable cells in a given sample. Therefore the GSH assay also 
served as a confirmatory assay for the ATP cell viability assay. Cyclosporine was also used as a positive control for this assay and 
showed a similar dose dependent reduction in GSH levels as was the case with cell viability (Figure 2A). Ugambu had a slightly 
significant (p< 0.01) effect on GSH content at higher doses while low doses increased intracellular GSH (Figure 2B). Product 
Blue stimulated intracellular levels of GSH in all treatment  
Changes in the levels of GSH of PBMCs treated with Ihashi and Product Nene tracked changes in cell viability as 
measured by the ATP assay (Figure 1D & E). Both traditional medicine preparations significantly (p< 0.001) reduced GSH levels 
at high doses while low doses were tolerated by treated immune cells when compared to untreated control cells (Figure 2D & E). 
SPNa and SDKc did not deplete intracellular GSH levels of PBMCs in all treatment doses when compared to untreated immune 
cells.  
    
Cytokines assay 
 
The use of the Multi-Analyte Profiler ELISArray assay kit allowed batch screening of the effects of traditional medicine 
preparations on pro-inflammatory cytokine secretion in PBMCs in an in vitro model. Changes in absorbance values of 
supernatants from treated PBMCs were compared to untreated control supernatants. Product Blue was the only product that did 
not show any significant changes in secretion of all 12 cytokines when compared to untreated samples. Ugambu, Ihashi, Product 
Nene, SPNa, and SDKc induced significant (p< 0.001) changes in pro-inflammatory cytokine secretion at very low treatment 
doses (Tables 1 and 2). Almost all these changes reflected an increase in cytokine secretion after treatment with dilutions of these 
traditional medicine preparations. 
 
 
Table 1: Results of the inflammatory cytokines assay from PBMCs supernatants of treated and untreated samples. Human 
PBMCs were treated with dilutions of Ugambu, Product Blue and Ihashi over 24 hours. Ugambu and Ihashi showed an 
ability to promote pro-inflammatory cytokine secretion at low doses while Product Blue did not show any significant 
change in most of the cytokines analysed.   
 
Ugambu Product Blue Ihashi 
Spectrophotometric absorbance readings 
 
 
Cytokines Control 1/200 1/500 Control 1/200 1/500 Control 1/200 1/500 
IL 1α 0.021286 0.125202* 0.155075* 0.021286 0.040323 0.019013 0.033957 0.019188 0.037379 
IL 1β 0.056427 0.67238* 0.673929* 0.056427 0.071787 0.033606 0.016937 0.026369 0.054548* 
IL 2 0 0 0 0 0.002887 0 0 0 0.010967* 
IL 4 0.0055906 0.035448* 0.043077* 0.005906 0.021286 0.018566 0.022376 0.015249 0.030553 
IL 6 2.291123 2.317117 2.328777 2.291123 2.292034 2.276336 0.313504 0.4006061 1.046472* 
IL 8 2.247801 2.252264 2.283699 2.247801 2.257167 2.275678 2.234766 2.195429 2.241874 
IL 10 0.140699 0.863191* 0.87614* 0.140699 0.17455 0.101955 0.040148 0.04316 0.071133* 
IL 12 0.005759 0.014285* 0.041226* 0.005759 0.024374 0 0.023157 0.035197 0.017104 
IL 17α 0.009282 0.005762 0.018934* 0.009282 0.027508 0 0.040553 0.032653 0.019679* 
IFN 0 0.021785* 0.0406* 0 0.004881 0 0.029434 0.035976 0.018466 
TNFα 0.158224 0.324455* 0.397102* 0.158224 0.054626 0.051161 0.01857 0.034654* 0.016679 
GM-CSF 0.011239 0.09674 0.124461* 0.011239 0.022104 0.025594 0.009118 0.049298* 0.017863 
*Significant change in absorbance readings for each cytokine as compared to untreated control sample    
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Figure 1: Graphical representation of the effects of traditional medicine preparations on ATP levels, which reflect cell viability, in PBMCs treated with different doses after 24 hours. The dose 
response curves represented include (A) cyclosporine, (B) Ugambu, (C) Product Blue, (D) Ihashi, (E) Product Nene, (F) SPNa, and (G) SDKc. Each graph includes an untreated control 
as a reference sample. Cyclosporine (positive control) induced a doses dependent decrease in cell viability while Ugambu and Product Blue did not affect cell viability in treated 
PBMCs. Ihashi, Product Nene and SDKc induced a dose dependent decrease in cell viability with high doses showing significant (p < 0.001) toxicity to treated PBMCs. SPNa doses 
were also significantly (p < 0.001) toxic to PBMCs even in low doses.       
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Figure 2: Changes in intracellular levels of glutathione (GSH) of treated and control samples of PBMCs after 24 hours of incubation. The dose response curves represented include (A) 
cyclosporine, (B) Ugambu, (C) Product Blue, (D) Ihashi, (E) Product Nene, (F) SPNa, and (G) SDKc. The positive control was cyclosporine and each graph included an untreated 
control as a reference sample. Ugambu high doses decreased GSH levels while low doses induced an increase in this intracellular antioxidant. Ihashi and Product Nene showed adose 
dependent effect on GSH levels with high doses significantly (p< 0.001) decreasing GSH content while low dose were tolerated by treated PBMCs. SPNa and SDKc did not change 
GSH content of treated PBMCs significantly from those of untreated cells.   
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Table 2: Cytokine analyses results from supernatants of PBMCs treated with doses of Product Nene, SPNa and SDKc over 24 
hours.    
   
Product Nene SPNa SDKc 
Spectrophotometric absorbance readings 
 
 
Cytokines Control 1/200 1/500 Control 1/200 1/500 Control 1/200 1/500 
IL 1α 0.002527 0.145798* 0.175523* 0.010246 0.030728 0.039901 0.010246 0.021322 0.032847* 
IL 1β 0.077016 2.259161* 2.28086* 0.029211 0.061474 0.091266 0.029211 0.074271* 0.095577* 
IL 2 0 0.008973 0.012604 0 0.014484 0.005585 0 0 0 
IL 4 0.0206 0.03648 0.023376 0 0.050615 0.047132 0 0.04001* 0.048964* 
IL 6 2.03003 2.314435* 2.306163* 0.200273 0.408549* 0.278515 0.200273 0.448786* 0.259028 
IL 8 1.509134 1.843873* 2.221598* 1.229702 1.532653 1.550086 1.229702 1.45217 1.234844 
IL 10 0.048767 0.978975* 0.627364* 0.006483 0.032181* 0.051847* 0.006483 0.07851* 0.079002* 
IL 12 0.013905 0.034357 0.017545 0.042441 0.044058 0.055228 0.042441 0.037429 0.041418 
IL 17α 0.00524 0.009919 0.012963 0.0307 0.117735* 0.050291 0.0307 0.072203* 0.058431* 
IFN 0 0.031149* 0.016341 0.018318 0.028502 0.035927 0.018318 0.050088* 0.059476* 
TNFα 0 1.0211* 0.484274* 0.041442 0.082701* 0.067795* 0.041442 0.093146* 0.073614* 
GM-CSF 0.001021 0.255015* 0.250927* 0.049034 0.043058 0.0684* 0.049034 0.080871* 0.075226* 
*Significant change in absorbance readings for each cytokine as compared to untreated control sample    
 
 
 
 XTT screening assay 
 
The screening assay measured the ability of the traditional medicinal preparations to protect MT-4 against HIV induced 
autolysis. Because the study was not designed to pinpoint the exact mechanism of action of each medicinal preparation, any 
antiretroval drug could be used as a positive control. Azidothymidine (AZT) was therefore chosen as a positive control. Ugambu, 
Ihashi, Product Nene, and SDKc showed the highest protective effect while SPNa and Product Blue had negligent or zero 
protective effect. These products had no significant protective effects and also had very low ability to selectively distinguish 
between infected and non-infected cells when compared to AZT (p> 0.05) (Table 3).    
  
 
 
 
 
 
 
Table 3: Results from the XTT screening assay 
 
Traditional medicine 
preparation 
IC50 (dilutions) EC50 (dilutions) SI 
AZT 0.044 4.43 x 10-5 1009 
1 Ugambu -3.589 -1.4 0.03 
2 SPNa -2.178 -2.6 2.02 
3 Ihashi -1.9 -3.5 13.1 
4 SDKc -1.83 -5.1 193 
5 Product Nene -3.08 -0.5 0.016 
6 Product Blue -0.429 - - 
 
 
HIV-1 Viral loads 
 
The purpose of the experiment was to assess antiviral activity and not mechanism(s) of action; hence any antiretroviral 
drug with known antiviral activity could be used, independent of its mechanism of action.  According to the adopted innovative 
method based on the on the algorithm for HIV viral load testing, one test is sufficient. It is important to note that the assay was 
setup in a diagnostic level 3 laboratory. The antiviral activity of herbal medicines was tested on MT-4 cells incubated with the 
HIV-1 virus and treated with several dilutions of traditional medicine preparations and compared to the antiviral drug AZT. 
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Ugambu, Ihashi, and Product Nene showed the highest antiviral activity. Over the five days of incubation, these products had 
higher antiviral activity than the positive control AZT (Figure 3). SDKc, SPNa and Product Blue did not show any significant 
antiviral properties when compared to AZT (Figure 3).  
 
 
 
 
Figure 3: Log10 HIV Viral loads of culture supernatant exposed to traditional medicine preparations 1 to 6 (as outlined in table 3)  
and AZT at 0, 1, 3 and 5 days following infection of MT-4 cells by HTLVIIIB. The concentration of the plant extracts 
Ugambu, SPNa, Ihashi, SDKc, Product Nene and Product Blue was equivalent to that of the EC50-1.4, -2.6, -3.5, -5.1, 
and -0.5. AZT had an EC50 of 4.43 x 10-5. 
 
 
 
Discussion 
 
Many plants used in traditional medicine preparations have immunostimulant and immunomodulatory properties. Such 
effects are important in altering the human immune response to fight infections such as HIV and AIDS (Bodeker et al., 2006). The 
purpose of this study was to evaluate properties of multiple component traditional medicine preparations prescribed by local THPs 
to patients with compromised immune systems. Traditional medicine preparations such Ugambu, Ihashi, Product Nene and SDKc 
showed a dose dependent effect in the levels of ATP and GSH in treated immune cells. High doses of these products were 
cytotoxic to PBMCs while high dilutions did not deplete either ATP or GSH. Such dose dependent responses are normal for most 
drugs as shown by the positive control, cyclosporine. Depletion of ATP and GSH levels also determine the type of cell death 
induced in treated cells. The same reagent might induce apoptosis at lower dose but induce cell death by necrosis at higher doses. 
This is probably due to the collapse of cellular integrity, including plasma membrane disruption, a large calcium influx, as well as 
intracellular ATP depletion (Tsujimoto, 1997).  
No significant cytoxicity was detected in PBMCs treated with dilutions of Product Blue. This product enhanced the 
levels of ATP and GSH content of all treated samples. While Product Blue may seem to enhance the ability of immune cells to 
resist infections, it did not modulate the production of cytokines at medium to low doses. Medicinal preparations Ugambu, Ihashi, 
Product Nene, SPNa and SDKc, which showed relative cytoxicity at high doses, were able to modulate pro-inflammatory 
cytokines at non-cytotoxic low doses. Immune cells treated with these products demonstrated increased secretion of IL 1β, IL 2, 
IL 8, IFN-γ, TNF-α, and GM-CSF (p< 0.001). Such inflammatory cytokines are multi-potential mediators of the cellular immune 
system with a wide variety of biological activities. Traditional herbal medicines which can stimulate the immune system through 
inducing cytokine production in healthy PBMCs may also have positive effects on HIV-infected patients (Barak et al., 2002; 
Liang et al., 2008). It is important to also note that the treated PBMCs in this study were not stimulated and therefore expected to 
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secrete less cytokines. A study by Hendricks and Pool (2010) on the effects of Rooibos tea on immune cells showed that 
cytokines are expressed at very low concentrations in unstimulated immune cells while stimulation with endotoxin 
lipopolysaccharide (LPS) dramatically increase cytokine expression. 
Traditional medicine preparations such as Ugambu, Ihashi, and Product Nene, which showed an ability to significantly 
modulate cytokine secretion in normal PBMCs, also had the highest antiviral activities of all the products tested. It is therefore 
possible that antiviral properties of these products is related to their ability modulate cytokine secretion in treated immune cells 
even though this study does not prove it. Multi-purpose traditional herbal preparations sold in South Africa showed potent activity 
against HIV reverse transcriptase (RT) enzyme (Ndhlala et al., 2010). It is important to note that the herbal preparations which 
showed high antiviral activities were also cytotoxic to normal immune cells. The same medicinal preparations had very low 
selective indexes in the XTT screening assay. Therefore finding an effective in vitro dose which does not affect viability of non-
infected cells requires a fine balance.  
 
Conclusion 
 
The data obtained from in vitro assays in this study has shown that some of the traditional medicines have at least one or 
all the properties of immunostimulation, immunomodulation or antiretroviral effects. Specific studies must be conducted to 
ascertain each mechanism of action of these multi herbal preparations because the data generated in this study suggest multiple 
sites of activity. Active metabolites involved in the observed biological effects must also be isolated. This work should directly 
involve the knowledge holders of the traditional medicines.   
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